These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response. García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677 [TBL] [Abstract][Full Text] [Related]
6. Role of homologous recombination in trabectedin-induced DNA damage. Tavecchio M; Simone M; Erba E; Chiolo I; Liberi G; Foiani M; D'Incalci M; Damia G Eur J Cancer; 2008 Mar; 44(4):609-18. PubMed ID: 18243687 [TBL] [Abstract][Full Text] [Related]
7. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines. Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ PLoS One; 2009 Sep; 4(9):e6967. PubMed ID: 19742314 [TBL] [Abstract][Full Text] [Related]
8. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Tavecchio M; Natoli C; Ubezio P; Erba E; D'Incalci M Cell Prolif; 2007 Dec; 40(6):885-904. PubMed ID: 18021177 [TBL] [Abstract][Full Text] [Related]
9. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin. Colmegna B; Uboldi S; Frapolli R; Licandro SA; Panini N; Galmarini CM; Badri N; Spanswick VJ; Bingham JP; Kiakos K; Erba E; Hartley JA; D'Incalci M Br J Cancer; 2015 Dec; 113(12):1687-93. PubMed ID: 26633559 [TBL] [Abstract][Full Text] [Related]
10. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478 [TBL] [Abstract][Full Text] [Related]
12. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695 [TBL] [Abstract][Full Text] [Related]
14. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136 [TBL] [Abstract][Full Text] [Related]
15. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Herrero AB; Martín-Castellanos C; Marco E; Gago F; Moreno S Cancer Res; 2006 Aug; 66(16):8155-62. PubMed ID: 16912194 [TBL] [Abstract][Full Text] [Related]
16. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer]. Gennigens C; Jerusalem G Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081 [TBL] [Abstract][Full Text] [Related]
17. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein. Erba E; Romano M; Gobbi M; Zucchetti M; Ferrari M; Matteo C; Panini N; Colmegna B; Caratti G; Porcu L; Fruscio R; Perlangeli MV; Mezzanzanica D; Lorusso D; Raspagliesi F; D'Incalci M Biochem Pharmacol; 2017 Nov; 144():52-62. PubMed ID: 28782526 [TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair. Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031 [TBL] [Abstract][Full Text] [Related]
19. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380 [TBL] [Abstract][Full Text] [Related]
20. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]